Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

AstraZeneca

Tracked across 82 events · 3389 articles · First seen Mar 09, 2018 · Last active Sep 23, 2026

Sentiment
12
Attention
8
Events
82
Relationships
82
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 30
Business
Impact: AstraZeneca expands its lung cancer portfolio with a novel oral EGFR inhibitor, complementing existing drugs like Tagrisso. The deal involves a $600M upfront payment and potential milestones, but does not affect 2026 guidance.
Jul 14, 2026 · 8 articles
7 -20
Business
Impact: AstraZeneca is the initiator of the merger talks, seeking to expand its US presence. Its shares fell over 7% on the news, reflecting investor skepticism about the deal's value and execution risk.
Aug 02, 2026 · 60 articles
4 -20
Business
Impact: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.
Aug 17, 2026 · 20 articles
4 20
Business
Impact: AstraZeneca is the primary developer and marketer of Tezspire. The successful trial could boost its pipeline credibility and support its $80 billion sales target by 2030, though shares were down slightly on the day.
Aug 27, 2026 · 6 articles
4 40
Business
Impact: AstraZeneca is the acquirer of worldwide rights to Sunvozertinib, expanding its lung cancer portfolio. The deal is expected to contribute to future growth without impacting 2026 guidance.
Sep 01, 2026 · 6 articles
6 80
Tech
AstraZeneca announced positive full results from the Phase III OBERON and TITANIA trials of tozorakimab, a first-in-class IL-33-targeting monoclonal antibody, in chronic obstructive pulmonary disease (COPD). Tozorakimab 300mg every four weeks reduced moderate and severe…
Impact: Developer of tozorakimab; positive trial results and FDA Priority Review acceptance strengthen its COPD pipeline and commercial prospects.
Sep 08, 2026 · 6 articles
4 -25
Tech
AstraZeneca announced on Friday, September 11, 2026, that its breast cancer drug Etcamah (camizestrant) failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The drug, tested in combination with…
Impact: AstraZeneca is the central entity of the event; its breast cancer drug Etcamah failed a late-stage trial, sending its U.S.-listed shares down 3% in aftermarket trading. The setback is seen by analysts as manageable and largely anticipated, with the long-term investment case intact.
Sep 11, 2026 · 6 articles
2 25
Regulatory
The International — European Commission approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) as a maintenance treatment for asthma in patients aged 12 years and older whose disease is not adequately controlled by a medium-dose inhaled…
Impact: Receives EU approval for Trixeo Aerosphere in asthma, expanding its respiratory portfolio and adding an incremental EU revenue stream; shares closed nearly flat at $168.37 on Tuesday.
Sep 23, 2026 · 10 articles
1 20
Business
Impact: AstraZeneca Malaysia collaborates with Danone — Alpro, reinforcing its commitment to addressing chronic kidney disease and hyperkalemia. The campaign may support its market position and brand image.
Aug 19, 2026 · 6 articles
4 70
Regulatory
Impact: AstraZeneca's drug ETCAMAH (camizestrant) is now paired with a companion diagnostic, enabling identification of ESR1-mutated breast cancer patients who may benefit. This approval could expand the drug's eligible patient population and support its commercial success.
Sep 04, 2026 · 8 articles
3 55
Business
Impact: AstraZeneca expands its oncology footprint in India, enhancing its brand and potential revenue from genomic diagnostics and AI solutions.
Jul 28, 2026 · 8 articles
4 30
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: As co-maker of Enhertu, AstraZeneca gains NHS Bret Engemann access for the drug, expanding its oncology market though at a negotiated price.
Sep 16, 2026 · 7 articles
6 70
Regulatory
Impact: AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.
Jul 02, 2026 · 6 articles
2 30
Business
Impact: AstraZeneca celebrated its February transfer to the New York Stock Exchange, which was the largest transfer by market capitalization in the exchange's history, indicating a positive move for the company's market presence.
Jun 05, 2026 · 10 articles
3 -30
Business
Impact: AstraZeneca's stock fell 5.7% after the trial failure; it faces investor investigations and potential legal liability.
Jul 09, 2026 · 46 articles
2 60
Business
Impact: AstraZeneca gains access to decentralized companion diagnostics for its oncology therapies, which could improve patient access and therapy adoption, supporting its drug sales and pipeline success.
Aug 04, 2026 · 8 articles
4 20
Tech
Impact: AstraZeneca is collaborating on the DURIPANC study, providing its drug Imfinzi, and stands to benefit from the success of the combination therapy.
Jun 01, 2026 · 10 articles
3 15
Business
Impact: AstraZeneca's cliramitug is the subject of the royalty acquisition; the deal does not directly affect AstraZeneca's financials but underscores the drug's commercial potential.
Jul 22, 2026 · 7 articles
2 40
Domestic
Impact: As a major pharmaceutical company, AstraZeneca can now sponsor researchers through the Global Talent visa, potentially enhancing its R&D capabilities.
Aug 05, 2026 · 6 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: One of the nine signatories of the open letter urging the European Union to boost pharmaceutical investment and speed up trials. The appeal signals concern over European competitiveness but does not change its near-term financial outlook.
Sep 22, 2026 · 6 articles
4 30
International
Impact: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.
Jan 30, 2026 · 9 articles
7 55
International
Impact: AstraZeneca featured an AI-powered drug discovery platform, advancing precision diagnostics and treatment.
Jun 15, 2026 · 87 articles
2 50
Business
Impact: AstraZeneca licensed TQC3721, an inhaled PDE3/4 inhibitor for COPD, from Sino Biopharmaceutical in a deal valued up to US$1.9 billion. This strengthens AstraZeneca's respiratory pipeline and aligns with its focus on chronic diseases.
Jul 20, 2026 · 6 articles
2 20
Business
Impact: AstraZeneca is a recipient of the 2026 Visionary Growth Leadership Best Practices Recognition, which could positively influence its brand image and investor perception.
Jun 15, 2026 · 6 articles
4 20
Regulatory
Impact: AstraZeneca benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Durvalumab and Olaparib therapies, potentially increasing the drugs' market reach.
Jun 11, 2026 · 6 articles
2 10
Business
Impact: Maria G. Belvisi previously served as Senior Vice President, Research & Development, Respiratory & Immunology at AstraZeneca, where she led the development of tozorakimab.
Apr 10, 2026 · 6 articles
3 -20
Regulatory
Impact: AstraZeneca's Lynparza faces generic competition if the tentative approval leads to final launch. The ongoing Paragraph IV litigation may delay market entry.
Jul 19, 2026 · 6 articles
1 10
Business
Impact: AstraZeneca participated in the symposium, contributing to discussions on decarbonization and green chemistry.
Jul 20, 2026 · 6 articles
2 5
Tech
A study published on Sept. 17, 2026 in Science identified the inherited EGFR T790M mutation as a major risk factor for lung cancer, especially in never-smokers. Researchers led by Jaclyn LoPiccolo and Pasi A. Jänne…
Impact: AstraZeneca's Tagrisso is an EGFR-targeted therapy mentioned in the context of treating EGFR-mutated lung cancer; the study may increase awareness and demand for such therapies.
Sep 17, 2026 · 6 articles
4 50
International
Impact: AstraZeneca executives participated in the Qingdao International City Partner Dialogue, engaging in discussions on sci-tech innovation and cooperation.
Jun 11, 2026 · 9 articles
+ 52 more events View on Dashboard
Pascal Soriot ↔ AstraZeneca
Pascal Soriot ↔ AstraZeneca
Roche ↔ AstraZeneca
Roche ↔ AstraZeneca
Moderna ↔ AstraZeneca
Moderna ↔ AstraZeneca
STOXX Europe 600 ↔ AstraZeneca
STOXX Europe 600 ↔ AstraZeneca
Pfizer ↔ AstraZeneca
Pfizer ↔ AstraZeneca
Novartis ↔ AstraZeneca
Novartis ↔ AstraZeneca
Sanofi ↔ AstraZeneca
Sanofi ↔ AstraZeneca
GAVI ↔ AstraZeneca
Merck Group ↔ AstraZeneca
GAVI ↔ AstraZeneca
Merck Group ↔ AstraZeneca
+ 52 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track AstraZeneca live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.